Mesenchymal stem cells in acute lung injury: are they ready for translational medicine?

Journal of Cellular and Molecular Medicine

Feng Xu¹  Yue Hu¹  Jiebai Zhou² 

[1] Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;Department of Respiratory Medicine, Zhongshan Hospital, Fudan University Medical School, Shanghai, China

关键词: mesenchymal stem cells;    acute lung injury;    inflammation;    infection;    toxins;   

DOI  :  10.1111/jcmm.12063

来源: Wiley

【 摘 要 】

Abstract

Acute lung injury (ALI) is a severe clinical condition responsible for high mortality and the development of multiple organ dysfunctions, because of the lack of specific and effective therapies for ALI. Increasing evidence from pre-clinical studies supports preventive and therapeutic effects of mesenchymal stem cells (MSCs, also called mesenchymal stromal cells) in ALI/ARDS (acute respiratory distress syndrome). Therapeutic effects of MSCs were noticed in various delivery approaches (systemic, local, or other locations), multiple origins (bone marrow or other tissues), or different schedules of administrations (before or after the challenges). MSCs could reduce the over-production of inflammatory mediators, leucocyte infiltration, tissue injury and pulmonary failure, and produce a number of benefit factors through interaction with other cells in the process of lung tissue repair. Thus, it is necessary to establish guidelines, standard operating procedures and evaluation criteria for translating MSC-based therapies into clinical application for patients with ALI.

【 授权许可】

CC BY   
© 2013 The Authors. Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.